IndraLab

Statements

reach
"While both Bufexamac and TSA treatment blocked IFN-beta promoter induction by SenV in a dose dependent manner, treatment of cells with VPA did not decrease IFN-beta promoter induction as compared to nontreated cells (XREF_FIG A)."
27372014
reach
"TSA treatment has been shown previously to block IFN-beta production."
27372014
reach
"TSA also blocked IFN-beta promoter induction by the constitutively active N-RIG construct but importantly, Bufexamac treatment did not block IFN-beta promoter induction by N-RIG."
27372014
reach
"Examination of additional microglial chemokine and antiviral genes (XREF_FIG and XREF_FIG, and XREF_FIG and XREF_FIG, respectively) demonstrated that IP-10, IFNbeta, IDO and viperin mRNA were all strongly inhibited by TSA and VA, whereas SB216763 had much less and insignificant effects."
20157787